Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
blinatumomab (blincyto) (1 trial)
COVID-19 convalescent plasma (1 trial)
Leukemia (Phase 2)
Leukemia, Lymphoid (Phase 2)
Philadelphia Chromosome (Phase 2)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)
Trials (2 total)
Trial APIs (2 total)